concept

ALPHA-SYNUCLEIN AGGREGATION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALPHA-SYNUCLEIN AGGREGATION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

54Connections

4Hypotheses

12Analyses

18Outgoing

36Incoming

0Experiments

17Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	ALPHA-SYNUCLEIN AGGREGATION

Pathway Diagram

graph TD
    ALPHA_SYNUCLEIN_AGGREGATION["ALPHA-SYNUCLEIN AGGREGATION"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"causes"| Parkinson_s_Disease["Parkinson's Disease"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"causes"| Neurodegeneration["Neurodegeneration"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"causes"| CNS_Inflammation["CNS Inflammation"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"interacts"| Mitochondrial_Dysfunction["Mitochondrial Dysfunction"]
    Short_Chain_Fatty_Acids["Short-Chain Fatty Acids"] -->|"modulates"| ALPHA_SYNUCLEIN_AGGREGATION
    BMAL1["BMAL1"] -->|"promotes"| ALPHA_SYNUCLEIN_AGGREGATION
    Piperine["Piperine"] -->|"inhibits"| ALPHA_SYNUCLEIN_AGGREGATION
    ceftriaxone["ceftriaxone"] -->|"inhibits"| ALPHA_SYNUCLEIN_AGGREGATION
    Polyamines["Polyamines"] -->|"modulates"| ALPHA_SYNUCLEIN_AGGREGATION
    Ceftriaxone["Ceftriaxone"] -->|"inhibits"| ALPHA_SYNUCLEIN_AGGREGATION
    SNCA["SNCA"] -->|"involved_in"| ALPHA_SYNUCLEIN_AGGREGATION

Outgoing (18)

Target	Relation	Type	Str
Parkinson's Disease	causes	disease	0.95
Parkinson's Disease	associated_with	disease	0.95
Mitochondrial Depolarization	causes	phenotype	0.93
Dopaminergic Neurons	causes	cell_type	0.92
ATP Production	downregulates	phenotype	0.90
Parkinson's Disease	causes	disease	0.90
microtubule destabilization	drives	process	0.90
Parkinson's Disease	contributes_to	disease	0.90
Autophagy-Lysosomal Pathway	involved_in	pathway	0.90
Mitochondrial Fragmentation	causes	phenotype	0.89
dopaminergic neuron loss	contributes_to	phenotype	0.85
CNS Inflammation	causes	process	0.85
Neurodegeneration	causes	process	0.85
Parkinson's disease	causes	disease	0.70
enteric neurons	causes	cell_type	0.70
CNS pathology	causes	mechanism	0.70
Enteric nervous system dysfunction	causes	mechanism	0.70
neurodegeneration in Substantia Nigra	causes	phenotype	0.70

Incoming (36)

Source	Relation	Type	Str
SNCA	involved_in	gene	0.95
lysosomal dysfunction	causes	mechanism	0.90
autophagy	prevents	pathway	0.90
D-520	suppresses	drug	0.90
Short-Chain Fatty Acids	modulates	compound	0.90
Piperine	inhibits	compound	0.90
autophagy pathway	prevents	pathway	0.90
TFEB	reduces	transcription_factor	0.90
BMAL1	promotes	gene	0.90
SNCA	causes	gene	0.90
SNCA	regulates	gene	0.85
ceftriaxone	inhibits	drug	0.85
BMAL1	inhibits	gene	0.85
SCFAS	inhibits	compound	0.80
gut microbiota	promotes	process	0.80
SNCA	involved_in	protein	0.80
Polyamines	modulates	compound	0.80
neuroinflammation	promotes	process	0.80
Ceftriaxone	inhibits	drug	0.80
microbiome restoration	inhibits	intervention	0.70
curli fibrils	causes	biomarker	0.70
propionate	reduces	metabolite	0.70
iron	causes	biomarker	0.70
TLR4 activation	activates	process	0.70
Dorsal Motor Nucleus of the Vagus Nerve	associated_with	cell_type	0.70
Olfactory Bulb	associated_with	cell_type	0.70
DOPAL	causes	metabolite	0.70
alpha-synuclein phosphorylation	causes	mechanism	0.70
germ-free mice	protective_against	model	0.70
Ferroptosis	modulates	process	0.70
inflammation	activates	mechanism	0.70
propionate	modulates	pathway	0.50
gut dysbiosis	activates	process	0.50
Microglial activation	promotes	process	0.50
Curli fibrils	causes	protein	0.50
Pro-inflammatory cytokines	promotes	biomarker	0.50

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
m6A-dependent control of alpha-synuclein transcript fate and	0.626	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Cell-state stratification is required to resolve m6A RNA Mod	0.612	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Glucosylceramide accumulation nucleates alpha-synuclein aggr	0.525	Parkinson's disease	GBA-Synuclein Loop Therapeutics for PD

Mentioning Analyses (12)

Scientific analyses that reference this entity

m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra

neurodegeneration | 2026-04-27 | 4 hypotheses Top: 0.662

Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation,

neurodegeneration | 2026-04-26 | 4 hypotheses Top: 0.630

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

neurodegeneration | 2026-04-24 | 6 hypotheses Top: 0.670

Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i

neurodegeneration | 2026-04-17 | 7 hypotheses Top: 0.559

Why does iron chelation therapy worsen outcomes in H63D HFE variant carriers des

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.586

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (17)

Multi-agent debates referencing this entity

How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA st

active · Rounds: 4 · Score: 0.67 · 2026-04-28

Hypothesis debate: Microbial Inflammasome Priming Prevention

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Hypothesis debate: SCFA Deficiency Disrupts Microglial Homeostasis and Promotes

closed · Rounds: 4 · Score: 0.60 · 2026-04-26

Hypothesis debate: Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propag

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Enteric Nervous System Dysfunction as Self-Reinforcing Pathol

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

What are the key molecular mechanisms by which gut microbiome dysbiosis drives n

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

closed · Rounds: 4 · Score: 0.63 · 2026-04-24

This analysis aims to elucidate the mechanisms by which gut microbiome dysbiosis

closed · Rounds: 4 · Score: 0.82 · 2026-04-22

The debate identified this as a critical mechanistic gap - TFEB may increase lys

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

Related Research

Hypotheses and analyses mentioning ALPHA-SYNUCLEIN AGGREGATION in their description or question text

No additional research found

ALPHA-SYNUCLEIN AGGREGATION

Understanding Entity Pages

Pathway Diagram

Outgoing (18)

Incoming (36)

Targeting Hypotheses (4)

Mentioning Analyses (12)

m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra

Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation,

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i

Why does iron chelation therapy worsen outcomes in H63D HFE variant carriers des

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

Which specific metabolic pathways in APOE4 microglia are causally linked to dysf

Does TFEB activation directly restore mutant GBA enzyme activity or only enhance

GBA-Synuclein Loop Therapeutics for PD

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (0)

Related Papers (0)

Debates (17)

How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA st

Hypothesis debate: Microbial Inflammasome Priming Prevention

Hypothesis debate: SCFA Deficiency Disrupts Microglial Homeostasis and Promotes

Hypothesis debate: Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propag

Hypothesis debate: Enteric Nervous System Dysfunction as Self-Reinforcing Pathol

Hypothesis debate: LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target

What are the key molecular mechanisms by which gut microbiome dysbiosis drives n

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

This analysis aims to elucidate the mechanisms by which gut microbiome dysbiosis

The debate identified this as a critical mechanistic gap - TFEB may increase lys

Related Research